Global Pulmonary Arterial Hypertension Market
Added: (Wed Jun 21 2023)
Pressbox (Press Release) -
Market Overview:
According to the latest research report published by DataM Intelligence, the Global Pulmonary Arterial Hypertension Market was valued at US$ 7,041.01 million in 2022 and is projected to reach US$ 10,596.1 million by 2030. The market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-
2030). The global pulmonary arterial hypertension market is segmented on the basis of drug class, route of administration, distribution channel, and region. North America is expected to contribute significantly to the market growth due to manufacturers are initiating several initiatives to provide healthcare practitioners with information and resources. Major players in the market include Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG, Pfizer
Inc, United Therapeutics Corporation.
Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (high blood pressure in the lungs). A multitude of blockages in the small arteries of the lung causes this increased vascular pressure in PAH.
Women aged 30-60 frequently have pulmonary arterial hypertension (PAH). Although there is no cure for PAH, interventions to alleviate symptoms and improve quality of life are available. PAH is classified as a Group 1. In the United States, 500-1000 new cases of PAH are discovered every year.
Market Drivers:
The rising incidence of pulmonary arterial hypertension is a major market driver. For instance, according to a recent analysis, the total incidence of pulmonary arterial hypertension was 14 occurrences per million, higher than the Reveal registry, with an odds ratio of 6.3 (95% CI: 4.2-9.5) (p.001).
The annual period prevalence of pulmonary arterial hypertension was 93 cases per million, higher than the REVEAL, odds ratio = 7.5 (95% CI: 6.4-8.8), and remained higher when the clinic cohort was restricted to patients with hemodynamic severity comparable to the REVEAL, odds ratio = 3.8 (95% CI:
3.0-4.6), (p.001).
Market Restraints:
One of the constraints is the drug's negative effects when used to treat pulmonary arterial hypertension. For example, according to the American College of Cardiology, sotatercept lowers pulmonary arterial hypertension mortality and clinical deterioration by 84%. The STELLAR study, which was in its third phase, randomly allocated 323 patients with WHO group I and WHO functional class II or III PAH who were receiving background PAH medication to sotatercept (Accutane). The first dosage was 0.3 mg/kg, followed by 0.7 mg/kg every three weeks.
Covid-19 Impact Analysis:
COVID-19 has significantly impacted the pulmonary arterial hypertension market, where certain dangers associated with COVID-19 in PAH patients are severe. In a US study of 77 PAH Comprehensive Care Centers, COVID-19 infection was 2.1 cases per 1,000 patients with PAH, equivalent to the frequency of COVID-19 infection in the general US population.
Although COVID-19 did not seem more common in PAH patients, mortality was higher at 12%.
Furthermore, 33% of PAH patients infected with COVID-19 were hospitalized. Because COVID-19 primarily affects the respiratory system, persons with pre-existing lung disorders such as PAH may be more prone to suffer significant repercussions if infected. It is critical to emphasize.
Russia-Ukraine Conflict Analysis:
Russia-Ukraine conflict analysis disrupted the PAH market with many factors like Disruption of healthcare infrastructure: Healthcare infrastructure in conflict-affected regions may be destroyed or strained due to the direct effects of war. Consequently, access to medical treatments, particularly specialist institutes capable of diagnosing and treating PAH, may be restricted.
Medication shortages: The battle could disrupt the supply chain for critical medications, particularly those used to treat PAH. This might result in drug shortages or difficulties getting crucial medications, leading to inadequate sickness treatment.
Recent Industry Developments:
1. The ICER examined Sotatercept for pulmonary arterial hypertension in May 2023. The Institute for Clinical and Economic Review (ICER) announced plans to assess the clinical efficacy and value of sotatercept, a novel investigational first-in-class drug for pulmonary arterial hypertension (PAH).
Sotatercept works by blocking aberrant signaling in the pulmonary blood vessels, which leads to an imbalance of growth-inhibitory and growth-promoting mediators like activins. Consequently, it interferes with the mechanism of PAH, which causes constriction of small blood vessels in the lungs, restricting blood flow from the right side of the heart.
2. Gossamer Bio intends to start Phase 3 PAH research with seralutinib in May 2023. Gossamer Bio plans to begin a Phase 3 clinical study of seralutinib (GB002), an experimental inhalation drug, in patients with pulmonary arterial hypertension (PAH) shortly. We are on track to begin seralutinib's Phase 3 clinical investigation in the coming months, bringing us one step closer to
our goal of offering a potential new therapy for PAH patients.
3. The US Food and Drug Administration (USFDA) approved Treprostinil injectable as a therapeutically equivalent generic version of Remodulin in April 2023. Dr. Reddy's new product is available in vials containing 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml, and 200 mg/20 ml.
Treprostinil injection is a prostacyclin mimic used to slow the rate of clinical deterioration in those who need to stop taking epoprostenol.
Patients with NYHA Functional Class II-IV symptoms and aetiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%), according to Dr. Reddy's information about studies proving its effectiveness.
Segmentation Analysis:
As per the research analysis, the global pulmonary arterial hypertension market is segmented by drug class into prostacyclin and prostacyclin analogs, calcium channel blockers, phosphodiesterase 5 (PDE-5), endothelin receptor antagonists (ERA), and others; by route of administration into inhalation, injectable,
and oral administration; and by distribution channel into hospital pharmacy, pharmacy stores, and others.
The market players lead the prostacyclin and prostacyclin analogs drug class segment, with a proportion of roughly 39.6% during the projected period. Prostacyclin and its analogs substantially influence the pulmonary arterial hypertension market, where epoprostenol treatment improves cardiovascular
factors, considerably lowers sensations of dyspnea and exhaustion, and promotes exercise tolerance in people with PAH. Other benefits include decreased total pulmonary and vascular resistance (PVR), decreased mPAP, and increased cardiac index and stroke volume.
SGC simulators, on the other hand, are expected to be the fastest-growing segment in the industry. SGC stimulation aids in segment formation by modulating physiological responses such as vascular smooth muscle, inflammatory suppression, and thrombosis.
Geographical Analysis:
The global pulmonary arterial hypertension market is segmented into North America, Europe, South America, Asia Pacific, and Middle East & Africa.
North America Pulmonary Arterial Hypertension Market:
North America is expected to occupy around 39.1% of the total market share throughout the projected period. According to the American Lung Association, PAH is a rare and progressive illness that accounts for 500-1000 new cases discovered in the United States each year. According to the same source,
around 15-20% of PAH patients have heritable PAH caused by genetic changes. Furthermore, manufacturers are initiating several initiatives to provide healthcare practitioners with information and resources, fueling market development. For example, the United Therapeutics-supported PAH Initiative
offers tools and knowledge to assist healthcare practitioners in treating PAH patients.
Competitive Landscape:
The major companies contributing to the global pulmonary arterial hypertension market growth include Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc, GlaxoSmithKline Plc, Actelion Pharmaceuticals, Ltd. (Johnson & Johnson), Merck & Co. Inc, Novartis International AG,
Pfizer Inc, and United Therapeutics Corporation.
Related Reports:
Global Pulmonary Drugs Market
Global Anti-Hypertension Drugs Market
Cardiopulmonary Resuscitation Devices Market
Global Idiopathic Pulmonary Fibrosis (IPF) Market
Additional Benefits Post Purchase:
1) Unlimited Analyst support for a period of 1 year.
2) Any query regarding the scope offered will be addressed within 24- 48 hours.
3) An Excel sheet with market numbers will be provided separately.
The Full Report has the below insights.
• The report offers a comprehensive evaluation of the market in terms of Market Value (US$)
and Y-o-Y Growth Rates (%). It does so via in-depth qualitative insights, historical data (2020-
2021) and verifiable market size projections (2022-2029).
• Visualize the composition of the global pulmonary arterial hypertension market
segmentation drug class, route of administration, distribution channel, and region,
highlighting the key commercial assets and players.
o By Drug Class: Prostacyclin and prostacyclin analogs, calcium channel blockers,
phosphodiesterase 5 (PDE-5), endothelin receptor antagonists (ERA), and others
o By Route of Administration: Inhalation, injectable, and oral administration
o By Distribution Channel: Hospital pharmacy, pharmacy stores, and others.
o By Region: North America, Europe, South America, Asia-Pacific, and Middle East and
Africa.
• Identify commercial opportunities in the global pulmonary arterial hypertension market by analyzing trends and co-development deals.
• The report also covers data insights on various industry forces such as Porter's five forces, regulations in each country, reimbursement scenario, technological advancements, PEST analysis and pricing analysis.
• Excel data sheet with thousands of the global pulmonary arterial hypertension market-level
4/5 segmentation data points.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in Excel for the key product of all major market players.
• The report will provide access to approximately 50+ market data tables, 40+ figures and close to 180 pages.
About DataM Intelligence:
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business
solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top
trademark trends, insights and developments to emancipate swift and astute solutions to clients like
you.
We encompass a multitude of Syndicate Reports & Customized Reports with a robust methodology. Our
research database features countless statistics and in-depth analyses across a wide range of 6300+
reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries;
catering to the key business research needs that influence the growth trajectory of our vast clientele.